IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Tybourne Capital Management HK Ltd.

Tybourne Capital Management HK Ltd. reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 150,790 shares of the medical research company’s stock after selling 2,100 shares during the quarter. IQVIA comprises 10.0% of Tybourne Capital Management HK Ltd.’s holdings, making the stock its 5th biggest holding. Tybourne Capital Management HK Ltd.’s holdings in IQVIA were worth $35,733,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. First Foundation Advisors grew its stake in shares of IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after buying an additional 43 shares in the last quarter. Invera Wealth Advisors LLC grew its position in shares of IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares during the period. Private Trust Co. NA increased its stake in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after purchasing an additional 47 shares during the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares during the period. Finally, Continuum Advisory LLC lifted its stake in IQVIA by 3.3% in the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after purchasing an additional 49 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on IQV shares. TD Cowen dropped their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Barclays dropped their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. BTIG Research reduced their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Friday, November 1st. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Price Performance

Shares of NYSE IQV opened at $201.44 on Thursday. The business has a fifty day moving average price of $220.36 and a two-hundred day moving average price of $226.57. The stock has a market capitalization of $36.56 billion, a PE ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.